Loading organizations...
Blue Ridge Capital operates as an investment partnership known for its global long-short equity strategy. It identifies market mispricings, taking long positions in undervalued companies and shorting overvalued ones. Its investment philosophy emphasizes deep fundamental research and understanding of economic trends, generating superior returns through disciplined stock selection.
John A. Griffin founded Blue Ridge Capital in 1996, leveraging a distinguished financial career. Before founding, Griffin spent nine years at Tiger Management, rising to President and earning recognition as a "Tiger Cub." His insight stemmed from applying rigorous, independent analysis and a global perspective to achieve exceptional investment performance.
The firm serves discerning institutional and high-net-worth investors seeking sophisticated capital management. Blue Ridge Capital’s vision prioritizes substantial long-term capital appreciation, managing portfolio risk. It employs a flexible, opportunistic investment framework, adapting to market shifts and leveraging analytical expertise to foster sustained value.
Blue Ridge Capital has 2 tracked investments across 1 company. The latest tracked deal is $30.0M Series C in Exosome Diagnostics in July 2017.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 1, 2017 | Exosome Diagnostics | $30.0M Series C | Forbion, Tiger Infrastructure Partners | Arcus Ventures, Btov Partners, CD Venture, NGN Capital |
| Jan 1, 2016 | Exosome Diagnostics | $16.0M Series B | — | Arcus Ventures, Forbion, CD Venture, NGN Capital, QIAGEN, Tiger Management |
